First-in-human study of CDNF in patients with Parkinson's disease
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs CDNF (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Herantis Pharma
- 12 Jun 2017 According to a Herantis Pharma media release,The participating patients will also be offered the possibility to participate in an extension study.
- 12 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017, according to a Herantis Pharma media release.
- 12 Jun 2017 According to a Herantis Pharma media release, The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, Sweden.